Literature DB >> 1344977

Liver involvement in infants with PiSZ phenotype of alpha 1-antitrypsin deficiency.

K Pittschieler1, G Massi.   

Abstract

Between July 1985 and June 1989, 19,432 newborns were screened during the first days of life to determine their Pi (protease inhibitor) phenotype. Fourteen infants were identified to be carriers of the PiSZ phenotype. Their clinical and biochemical follow-up data were recorded at 2, 5, and 12 months of age; only one case underwent a liver biopsy due to repeated abnormal liver enzymes. Three of 14 PiSZ infants showed some hepatic dysfunction at 2 and 5 months of age, but at 12 months all patients had normal liver function tests. None of them had clinical, biochemical, or morphological signs of neonatal cholestasis. The clinical and biochemical data related to the liver involvement are similar to those of the PiMZ phenotype, though the serum levels of alpha 1-antitrypsin in PiSZ carriers match those of the PiZZ group.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1344977     DOI: 10.1097/00005176-199210000-00014

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  3 in total

1.  Outcome of PiSS and PiSZ alpha-1-antitrypsin deficiency presenting with liver involvement.

Authors:  Nedim Hadzic; Ruggiero Francavilla; Susan M Chambers; Stefania Castellaneta; Bernard Portmann; Giorgina Mieli-Vergani
Journal:  Eur J Pediatr       Date:  2005-02-15       Impact factor: 3.183

2.  Serum levels of alpha1-antitrypsin predict phenotypic expression of the alpha1-antitrypsin gene.

Authors:  Steven J Steiner; Sandeep K Gupta; Joseph M Croffie; Joseph F Fitzgerald
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

Review 3.  Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype.

Authors:  Gerard N McElvaney; Robert A Sandhaus; Marc Miravitlles; Gerard M Turino; Niels Seersholm; Marion Wencker; Robert A Stockley
Journal:  Eur Respir J       Date:  2020-06-18       Impact factor: 16.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.